Dr. Fauci is cautiously optimistic about Moderna’s new crown candidate vaccine

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), is one of the main and most popular members of the White House Coronary Virus Task Force,media BGR reported. Fauci has appeared regularly on television and in interviews detailing efforts to stop the spread of COVID-19 and to find treatments for new coronaviruses. He has talked on several occasions about the feasibility of a vaccine, most recently saying that the first vaccine could arrive in a few months. He also co-authored a paper detailing plans for this particular type of COVID-19 drug, which he says may not be enough for a single vaccine to meet the world’s needs.

Dr. Fauci is cautiously optimistic about Moderna's new crown candidate vaccine

A few months ago, Moderna’s candidate vaccine was the first to enter a phase 1 human trial, and the company released early results earlier this week. NIAID did not comment on the matter at the time, but Now Mr Fauci said he was cautiously optimistic about the matter. “The question is, is it safe right away?” Obviously, it’s safe,” Fauci told CNN. “But importantly, it induces a reaction. You’ll predict that it will protect the virus, which is called neutralizing antibodies. “

He went on to explain that vaccines should “train” the immune system to produce different types of antibodies. As the name suggests, binding antibodies bind to pathogens, but do not prevent them from interacting with human cells. Neutralizing antibodies is the antibody you want, and it binds to the virus’s S protein so that it can attach to the cells. Moderna’s vaccine produced “a reasonable dose of neutralizing antibodies,” Fauci explains, which is why he is cautiously optimistic about the results.

Earlier this week, Moderna came under fire after reporting its early findings in a press release rather than a study. The company provided only limited results from eight of the 45 volunteers who received different doses of the candidate RNA vaccine, which produced neutralizing antibodies. The company did not explain whether the antibodies were enough to block the virus. The company also did not say when it would publish a study in the medical journal.

At the time, it was also noted that NIAID had not commented on the vaccine candidate, although the agency was one of Moderna’s partners in the work. In contrast, Fauci himself detailed the findings of the Redsey wee experiment before the study was published — a study that has not yet been released.

Although it took a few days, Fauci now has a view on the results, explaining: “Although the number is limited, it’s pretty good news because it reaches and crosses an important barrier in vaccine development.” That’s why I’m cautiously optimistic about it. “

If all goes well, the first COVID-19 vaccine could be available as early as early 2021, Mr. Fauci has said in a previous interview. He explained in another interview that it was Moderna’s drugs that gave him that hope. Fauci and some of his colleagues wrote a paper describing the difficult task of creating a COVID-19 vaccine. This process includes research and development steps, but also ensure shipping capacity and logistics delivery is in place. A single COVID-19 vaccine is not enough to meet demand, they write.

More research is needed to prove that Moderna’s candidate vaccine is a viable option for preventing COVID-19. The U.S. government has also invested in other vaccine candidates. Earlier this week, the U.S. invested $1.2 billion through AstraZeneca to get 300 million doses of Oxford’s promising new coronavirus vaccine. Like Moderna’s drugs, the Oxford University vaccine is currently in clinical trials, and researchers have not released any results on its efficacy or safety on the human body. There is no guarantee that any of these candidate drugs will work.